NTRA: Natera, Inc.
About
Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in Austin, TX.
Current Value
$163.831 Year Return
Current Value
$163.831 Year Return
Key Details
Market Cap
$21.40B
P/E Ratio
-91.39
1Y Stock Return
200.46%
1Y Revenue Growth
54.94%
Dividend Yield
0.00%
Price to Book
22.9
Strategies that include NTRA
Stock's related to NTRA
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ORGO | 46.22% | $540.91M | +59.38% | 0.00% |
| TSEM | 42.56% | $5.19B | +69.60% | 0.00% |
| VERX | 41.79% | $7.99B | +89.70% | 0.00% |
| PDFS | 40.24% | $1.17B | -2.56% | 0.00% |
| ADMA | 40.03% | $4.88B | +423.60% | 0.00% |
| PSTG | 39.42% | $16.35B | +36.41% | 0.00% |
| KODK | 39.24% | $422.90M | +41.40% | 0.00% |
| OKTA | 39.16% | $12.66B | +4.91% | 0.00% |
| MKSI | 38.69% | $7.29B | +42.89% | 0.82% |
| MRSN | 38.65% | $274.24M | +40.51% | 0.00% |
| NVMI | 38.11% | $5.16B | +44.02% | 0.00% |
| ESTA | 37.96% | $968.33M | +54.98% | 0.00% |
| SG | 37.28% | $4.38B | +299.68% | 0.00% |
| VVV | 37.05% | $4.98B | +11.54% | 0.00% |
| SPXC | 36.67% | $7.79B | +95.19% | 0.00% |
| RKLB | 36.57% | $10.25B | +386.94% | 0.00% |
| ISRG | 36.50% | $191.92B | +72.80% | 0.00% |
| ALGM | 36.46% | $3.59B | -31.01% | 0.00% |
| ENTG | 36.39% | $15.01B | -2.88% | 0.41% |
| CDNA | 36.09% | $1.18B | +132.21% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SNY | -0.01% | $120.34B | +3.11% | 4.25% |
| LUMO | -0.04% | $37.45M | +41.97% | 0.00% |
| JBSS | -0.07% | $949.98M | -9.36% | 1.04% |
| LNG | 0.08% | $49.37B | +24.99% | 0.82% |
| LEG | 0.09% | $1.54B | -50.75% | 9.00% |
| WTW | -0.12% | $30.98B | +26.60% | 1.13% |
| TCS | 0.20% | $14.81M | -84.46% | 0.00% |
| ACGL | -0.23% | $36.00B | +16.84% | 0.00% |
| SPH | 0.24% | $1.15B | +6.07% | 7.25% |
| FLUX | 0.24% | $37.37M | -36.18% | 0.00% |
| AJG | 0.26% | $64.17B | +17.51% | 0.80% |
| AGX | -0.29% | $2.01B | +224.91% | 0.85% |
| BNED | -0.41% | $277.22M | -91.94% | 0.00% |
| MBI | 0.41% | $335.78M | +105.79% | 0.00% |
| COR | -0.42% | $47.48B | +21.20% | 0.86% |
| PTMN | 0.43% | - | - | 16.06% |
| CVS | 0.45% | $70.18B | -18.08% | 4.72% |
| TBPH | 0.45% | $487.81M | -3.50% | 0.00% |
| EZPW | -0.57% | $655.76M | +45.24% | 0.00% |
| LFVN | -0.61% | $169.84M | +130.61% | 1.10% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| XEL | -17.57% | $41.42B | +15.91% | 3.12% |
| EDSA | -15.22% | $7.11M | -21.79% | 0.00% |
| FDP | -14.20% | $1.62B | +45.67% | 2.97% |
| HUSA | -13.41% | $16.69M | -11.56% | 0.00% |
| IRWD | -13.24% | $609.71M | -59.34% | 0.00% |
| SYRS | -13.09% | $7.43M | -90.46% | 0.00% |
| WRB | -12.47% | $22.94B | +29.98% | 0.69% |
| CBOE | -12.39% | $21.46B | +15.84% | 1.11% |
| GRFS | -11.54% | $2.18B | -11.41% | 0.00% |
| COLL | -11.14% | $959.44M | +16.71% | 0.00% |
| MCK | -11.10% | $78.15B | +35.51% | 0.42% |
| HMN | -10.98% | $1.65B | +24.56% | 3.34% |
| CQP | -10.66% | $25.90B | -6.77% | 5.96% |
| GAN | -10.65% | $83.39M | +21.19% | 0.00% |
| IMNN | -10.51% | $10.02M | -22.89% | 0.00% |
| MGNX | -9.99% | $218.42M | -53.04% | 0.00% |
| JRVR | -9.61% | $168.34M | -52.25% | 4.52% |
| LTM | -9.40% | $8.51B | -100.00% | <0.01% |
| CB | -8.99% | $114.43B | +26.00% | 1.24% |
| DAVA | -8.86% | $1.16B | -59.28% | 0.00% |
ETF's related to NTRA
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| IBDP | -0.03% | $2.11B | 0.1% |
| UNG | 0.06% | $908.80M | 1.06% |
| DFSD | 0.06% | $3.63B | 0.16% |
| DBA | 0.17% | $755.88M | 0.93% |
| JPST | 0.32% | $28.43B | 0.18% |
| GBIL | 0.37% | $5.60B | 0.12% |
| CORN | 0.46% | $61.12M | 0.2% |
| IBTG | -0.53% | $1.48B | 0.07% |
| SHV | -0.58% | $18.13B | 0.15% |
| GSY | 0.60% | $2.29B | 0.23% |
| SCHO | -0.72% | $11.10B | 0.03% |
| VGSH | 0.77% | $19.14B | 0.04% |
| AGZ | 0.92% | $708.37M | 0.2% |
| IBTH | 1.00% | $1.08B | 0.07% |
| SGOV | -1.07% | $27.53B | 0.09% |
| UTWO | -1.11% | $447.63M | 0.15% |
| WEAT | -1.13% | $120.27M | 0.28% |
| IVOL | -1.33% | $548.70M | 1.02% |
| VTIP | 1.39% | $11.71B | 0.04% |
| YEAR | -1.44% | $1.13B | 0.25% |
News
Yahoo
Natera, Inc. ( NASDAQ:NTRA ) just released its quarterly report and things are looking bullish. Revenue crushed...
Yahoo
Insight into Druckenmiller's Latest 13F Filings and Portfolio Adjustments
Yahoo
Natera ( NASDAQ:NTRA ) Third Quarter 2024 Results Key Financial Results Revenue: US$439.8m (up 64% from 3Q 2023). Net...
Yahoo
Massive revenue growth, surging margins, and groundbreaking cancer breakthroughs--Natera's unstoppable rise is turning heads
Finnhub
AUSTIN, Texas - Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced the completion of a study using Signatera from the CALGB /SWOG 80702 randomized, phase III clinical...
Yahoo
Natera Inc (NTRA) reports a 64% revenue increase and raises annual guidance, driven by robust oncology test performance and improved gross margins.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.